Adaptimmune Therapeutics plc
ADAP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $135,915 | $159,451 | $235,362 | $584,271 |
| - Cash | $91,139 | $143,991 | $108,033 | $149,948 |
| + Debt | $74,209 | $25,235 | $23,077 | $25,468 |
| Enterprise Value | $118,985 | $40,695 | $150,406 | $459,791 |
| Revenue | $178,032 | $60,281 | $27,148 | $6,149 |
| % Growth | 195.3% | 122% | 341.5% | – |
| Gross Profit | $177,962 | $50,424 | -$100,578 | -$104,941 |
| % Margin | 100% | 83.6% | -370.5% | -1,706.6% |
| EBITDA | -$52,665 | -$128,198 | -$155,593 | -$155,679 |
| % Margin | -29.6% | -212.7% | -573.1% | -2,531.8% |
| Net Income | -$70,814 | -$113,871 | -$165,456 | -$158,090 |
| % Margin | -39.8% | -188.9% | -609.5% | -2,571% |
| EPS Diluted | -0.28 | -0.57 | -1.02 | -1.02 |
| % Growth | 50.9% | 44.1% | 0% | – |
| Operating Cash Flow | -$73,206 | -$140,880 | -$141,769 | $10,729 |
| Capital Expenditures | -$2,720 | -$4,880 | -$29,740 | -$8,781 |
| Free Cash Flow | -$75,926 | -$145,760 | -$171,509 | $1,948 |